PRRU.F Stock Overview
A late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Immutep Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.18 |
| 52 Week High | AU$0.28 |
| 52 Week Low | AU$0.17 |
| Beta | 1.93 |
| 11 Month Change | -18.79% |
| 3 Month Change | -15.49% |
| 1 Year Change | -3.02% |
| 33 Year Change | -53.80% |
| 5 Year Change | n/a |
| Change since IPO | 207.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| PRRU.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -18.8% | 1.6% | 2.3% |
| 1Y | -3.0% | 23.6% | 35.1% |
Return vs Industry: PRRU.F underperformed the US Biotechs industry which returned 21.4% over the past year.
Return vs Market: PRRU.F underperformed the US Market which returned 31.5% over the past year.
Price Volatility
| PRRU.F volatility | |
|---|---|
| PRRU.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: PRRU.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine PRRU.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | n/a | Marc Voigt | www.immutep.com |
Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alpha (efti or IMP321), a soluble LAG-3lg fusion based, which is in clinical development for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma.
Immutep Limited Fundamentals Summary
| PRRU.F fundamental statistics | |
|---|---|
| Market cap | US$277.22m |
| Earnings (TTM) | -US$28.07m |
| Revenue (TTM) | US$2.52m |
109.8x
P/S Ratio-9.9x
P/E RatioIs PRRU.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRRU.F income statement (TTM) | |
|---|---|
| Revenue | AU$3.84m |
| Cost of Revenue | AU$41.55m |
| Gross Profit | -AU$37.70m |
| Other Expenses | AU$5.01m |
| Earnings | -AU$42.72m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.029 |
| Gross Margin | -981.42% |
| Net Profit Margin | -1,111.87% |
| Debt/Equity Ratio | 0.5% |
How did PRRU.F perform over the long term?
See historical performance and comparison